INmune Bio Company Insiders

INmune Bio Management Team Effectiveness

The company has return on total asset (ROA) of (0.5059) % which means that it has lost $0.5059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5577) %, meaning that it created substantial loss on money invested by shareholders. INmune Bio's management efficiency ratios could be used to measure how well INmune Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of January 14, 2026, Return On Tangible Assets is expected to decline to -1.73. The current year's Return On Capital Employed is expected to grow to -1.44. At present, INmune Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 26.9 M, whereas Total Assets are forecasted to decline to about 41.8 M. As of January 14, 2026, Common Stock Shares Outstanding is expected to decline to about 13.9 M. The current year's Net Loss is expected to grow to about (23.3 M)INmune Bio has a total of 26.59 Million outstanding shares. INmune Bio retains 17.01 (percent) of its outstanding shares held by insiders and 17.56 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as INmune Bio in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of INmune Bio, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

INmune Bio Workforce Comparison

INmune Bio Insider Trading

INmune Bio Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as INmune Bio often depends on how effective the management is. INmune Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of INmune management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the INmune management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of INmune Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, INmune Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of INmune Bio's management manipulating its earnings.

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.